Lipocine’s LPCN 1148 Gains Fast Track Designation

The latest update is out from Lipocine ( (LPCN) ).

Lipocine Inc. announced that its development candidate LPCN 1148, aimed at treating men with cirrhosis, is featured in the June 2025 edition of Hepatology. The candidate, which is targeted as a ‘First in Class’ product for overt hepatic encephalopathy and sarcopenia, has shown promising results in a Phase 2 trial. With the FDA granting fast track designation, LPCN 1148 is gaining recognition for its potential to improve outcomes for patients with cirrhosis, highlighting Lipocine’s innovative approach in addressing unmet medical needs in this area.

The most recent analyst rating on (LPCN) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Lipocine stock, see the LPCN Stock Forecast page.

Spark’s Take on LPCN Stock

According to Spark, TipRanks’ AI Analyst, LPCN is a Neutral.

Lipocine’s financial recovery is promising, with a strong balance sheet and reduced operational volatility. However, challenges remain in achieving consistent profitability and cash flow generation. Technical indicators show mixed signals, and the high P/E ratio suggests overvaluation, creating a cautious outlook.

To see Spark’s full report on LPCN stock, click here.

More about Lipocine

Lipocine Inc. is a biopharmaceutical company that leverages its proprietary technology platform to enable effective oral delivery of therapeutics. The company focuses on developing drug candidates that offer differentiated, patient-friendly oral delivery options targeting large addressable markets with significant unmet medical needs.

Average Trading Volume: 28,527

Technical Sentiment Signal: Sell

Current Market Cap: $19.48M

Find detailed analytics on LPCN stock on TipRanks’ Stock Analysis page.